Brind.

FDA and EMA granted Rare Pediatric Disease and Orphan Drug Designations to Quoin Pharmaceuticals Ltd.

1 report, 1 independent Updated Aug 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA EMA

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
EMA
Japanese vocalist of the group DUSTCELL

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 7GlobeNewswireQuoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update - Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second